Testing effectiveness (Phase 2)Not Yet RecruitingNCT07644208
What this trial is testing
PD-1/IL-2 Bispecific Antibody as Neoadjuvant Therapy for Early Recurrent Hepatocellular Carcinoma After Curative Hepatectomy
Who this might be right for
Hepatocellular Carcinoma (HCC)
Shanghai Zhongshan Hospital 30